Protagonist Therapeutics, Inc.
NASDAQProtagonist Therapeutics heads into its May 7 Q1 earnings with options markets flashing the most defensive signal of the past year. The put/call ratio has surged to 1.48 — nearly at its 52-week high and almost two standard deviations above the 20-day average of 0.80. That marks a dramatic shift from as recently as mid-April, when the PCR ran below 0.45. The flip happened fast: the…
Snapshot as of 6 May 2026
Protagonist Therapeutics heads into its May 7 Q1 earnings with options markets flashing the most defensive signal of the past year. The put/call ratio has surged to 1.48 — nearly at its 52-week high and almost two…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PTGX — free to start on ORTEX.
Sign up for free →Open PTGX on ORTEX